Results 1 to 10 of about 12,782 (146)

Incidence, clinical features, risk factors, and outcomes of Intraocular inflammation following Brolucizumab in Indian eyes – A multicentric study

Indian Journal of Ophthalmology, 2023
Purpose: To report the incidence, clinical features, potential risk factors, and outcomes of intraocular inflammation (IOI) following brolucizumab in Indian eyes. Methods: All consecutive patients diagnosed with brolucizumab-induced IOI from 10 centers
Debdulal Chakraborty, Soumen Mondal, Sabyasachi Sengupta, Zahir Abbas, Khushboo Chandra, Subhendu Boral, Aniruddha Maiti, Sangeeta Roy, Angshuman Mukherjee, Arnab Das, Somnath Chakraborty, Pinaki Nag   +11 more
doaj   +1 more source

Software pipeline for predicting and analyzing the structure of the receptor–ligand

Учёные записки Казанского университета: Серия Физико-математические науки, 2022
It is of fundamental importance in pharmacology and theoretical biology to analyze the binding of ligands to receptors. A better understanding of this process and its outcomes can help predict the following: how the protein interacts with ligands ...
A.S. Kozlova, A.R. Mukhametgalieva, A.N. Fattakhova, N.I. Akberova   +3 more
doaj   +1 more source

Patterns of treatment discontinuation in patients receiving anti-vascular endothelial growth factor for neovascular age-related macular degeneration

Indian Journal of Ophthalmology, 2022
Purpose: To report the reasons for treatment discontinuation within 5 years in patients receiving intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy for neovascular age-related macular degeneration (nAMD).
Narendra Dhingra, Deepa Upasani, Faruque D Ghanchi   +2 more
doaj   +1 more source

Ten-year outcome of anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration

Indian Journal of Ophthalmology, 2021
Purpose: The aim of this study was to report the 10-year visual outcome in eyes treated with anti-vascular endothelial growth factor (anti-VEGF) agents for neovascular age-related macular degeneration (nAMD) and to assess the impact of switching ...
Deepa Upasani, Narendra Dhingra
doaj   +1 more source

Incidence and prevalence of neovascular age-related macular degeneration: 15-year epidemiological study in a population-based cohort in Finland

Annals of Medicine, 2023
Background/objectives Neovascular age-related macular degeneration (nAMD) is a common cause for visual impairment in the ageing population. An increasing number of nAMD patients causes significant health burden, although intravitreal anti-VEGF agents ...
Ida Korva-Gurung, Anna-Maria Kubin, Pasi Ohtonen, Nina Hautala   +3 more
doaj   +1 more source

Pachychoroid neovasculopathy versus macular neovascularization in age-related macular degeneration with and without shallow irregular pigment epithelial detachment

Scientific Reports, 2023
To compare the choroidal neovascular features of individuals with pachychoroid neovasculopathy (PNV) and neovascular age-related macular degeneration (nAMD) with and without shallow irregular pigment epithelial detachment (SIPED). Using optical coherence
Hamid Riazi-Esfahani, Esmaeil Asadi Khameneh, Fariba Ghassemi, Mohammadreza Mehrabi Bahar, Ali torkashvand, Alireza Mahmoudi, Ahmed Husein Ahmed, Shahin Faghihi, Masoud Rahimi, Ali Akbarzadeh, Hooshang Faghihi, Elias Khalili Pour   +11 more
doaj   +1 more source

Integrative metabolome and lipidome analyses of plasma in neovascular macular degeneration

Heliyon, 2023
Age-related macular degeneration (AMD) causes irreversible vision-loss among the elderly in industrial countries. Neovascular AMD (nAMD), which refers to late-stage AMD, is characterized by severe vision-threatening choroidal neovascularization (CNV ...
Tantai Zhao, Jiani Li, Yanbin Wang, Xiaojian Guo, Yun Sun   +4 more
doaj   +1 more source

Anti-VEGF therapy of neovascular age-related macular degeneration: from randomized trials to routine clinical practice

Российский офтальмологический журнал, 2019
Antivasoproliferative therapy is a revolutionary trend in the treatment of neovascular age-related macular degeneration (nAMD), as it is aimed at blocking growth factors of the newly formed vessels.
R. R. Fayzrakhmanov
doaj   +1 more source

Through the Eyes of Patients: Understanding Treatment Burden of Intravitreal Anti-VEGF Injections for nAMD Patients in Norway

Clinical Ophthalmology, 2023
Gudrun Reitan,1 Inga Britt Kjellevold Haugen,2 Kristoffer Andersen,3 Ragnheidur Bragadottir,4,5 Christian Bindesbøll3 1Department of Molecular Medicine, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway; 2Department of Research, The ...
Reitan G, Kjellevold Haugen IB, Andersen K, Bragadottir R, Bindesbøll C   +4 more
doaj  

Comparison of cytokine levels in the aqueous humor of polypoidal choroidal vasculopathy and neovascular age-related macular degeneration patients

BMC Ophthalmology, 2020
Background The concentrations of cytokines in the aqueous humor from neovascular age-related macular degeneration (nAMD) and polypoidal choroidal vasculopathy (PCV) may vary. The study was conducted to compare various cytokine levels in the aqueous humor
Huiying Zhou, Xinyu Zhao, Mingzhen Yuan, Youxin Chen   +3 more
doaj   +1 more source